Selected article for: "acute respiratory syndrome coronavirus and low toxicity"
Author: Zheng, Lei; Chen, Yanmei; Bao, Jingxiao; He, Liping; Dong, Suzhen; Qi, Yifei; Zhang, John Z. H.
Title: Discovery of novel inhibitors of SARS-CoV-2 main protease
  • Cord-id: db6qryoj
  • Document date: 2021_9_2
    • ID: db6qryoj
    Snippet: Corona Virus Disease 2019 (COVID-19), referred to as ‘New Coronary Pneumonia’, is a type of acute infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. M(pro) is one of the main targets for treating COVID-19. The current research on M(pro) mainly focuses on the repurposing of old drugs, and there are only a few novel ligands that inhibit M(pro). In this research, we used computational free energy calculation to screen a compound library agai
    Document: Corona Virus Disease 2019 (COVID-19), referred to as ‘New Coronary Pneumonia’, is a type of acute infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. M(pro) is one of the main targets for treating COVID-19. The current research on M(pro) mainly focuses on the repurposing of old drugs, and there are only a few novel ligands that inhibit M(pro). In this research, we used computational free energy calculation to screen a compound library against M(pro), and discovered four novel compounds with the two best compounds (AG-690/13507628 and AG-690/13507724) having experimental measured IC(50) of just under 3 μM and low cell toxicity. Detailed decomposition of the interactions between the inhibitors and M(pro) reveals key interacting residues and interactions that determine the activity. The results from this study should provide a basis for further development of anti-SARS-CoV-2 drugs. Communicated by Ramaswamy H. Sarma

    Search related documents:
    Co phrase search for related documents
    • active compound and low cytotoxicity: 1, 2
    • active compound and low toxicity: 1
    • active non active and acute respiratory syndrome: 1
    • active non and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active non and low toxicity: 1
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and low cytotoxicity: 1, 2
    • active site and low nanomolar: 1, 2, 3, 4
    • active site and low toxicity: 1, 2
    • acute respiratory syndrome and additional screening: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and admet property: 1, 2
    • acute respiratory syndrome and low cytotoxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and low nanomolar: 1, 2, 3
    • acute respiratory syndrome and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25